Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, has announced an exclusive distribution agreement with CNX Therapeutics to supply selected oncology products across Central & Eastern Europe (CEE) and Turkey. The partnership represents a significant expansion of cancer treatment access in these regions through Er-Kim's established distribution infrastructure.
Strategic Partnership Details
The agreement creates an exclusive partnership for a portfolio of oncology-related medications, including CNX Therapeutics' Cardioxane (dexrazoxane) and Savene (dexrazoxane), which are part of CNX's established oncology portfolio. Through this partnership, treatments will now be distributed across all CEE markets, expanding therapeutic options for cancer patients in the region.
"A trusted partner and dedicated provider of oncology treatments in the region, Er-Kim has been bringing innovative oncology-related medications to emerging EMEA for 40 plus years, and we are always looking for strategic collaborations that enhance our dedication to these markets," said Mert Zorlular, President & CFO of Er-Kim. "We are excited about our partnership with CNX Therapeutics to support the expansion of its strong portfolio of pharmaceutical options for people with cancer as we strive to improve their well-being and quality of life."
Market Expansion Strategy
Pete Butterfield, Chief Operating Officer at CNX Therapeutics, emphasized the commercial significance of the partnership. "This partnership represents a significant step forward in expanding our commercial reach. Er-Kim's extensive regional network across Central and Eastern Europe will enable us to access new markets through their established distribution infrastructure. This is just the beginning of what we expect to be a highly successful partnership."
Company Background and Capabilities
Established in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, setting new commercialization and patient access standards. The company has built strategic partnerships with over 40 global leaders and distributes more than 68 products to 50+ countries, revolutionizing patient care in international markets by solving complex distribution challenges. Er-Kim maintains a dedicated team of over 300 professionals worldwide and generates revenues exceeding EUR 305M.
The partnership leverages Er-Kim's four decades of experience in bringing innovative oncology-related medications to emerging EMEA markets, positioning both companies to enhance cancer treatment accessibility across Central & Eastern Europe and Turkey through proven distribution networks and regional expertise.
